Published in J Virol on March 01, 1996
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol (2000) 2.11
In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol (1998) 1.73
Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. J Virol (1998) 1.72
Recombinant measles viruses with mutations in the C, V, or F gene have altered growth phenotypes in vivo. J Virol (1998) 1.62
Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci U S A (2003) 1.58
The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med (1997) 1.55
Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol (2007) 1.45
Nef enhances human immunodeficiency virus replication and responsiveness to interleukin-2 in human lymphoid tissue ex vivo. J Virol (1999) 1.43
Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS One (2007) 1.40
Mechanism of human immunodeficiency virus type 1 localization in CD4-negative thymocytes: differentiation from a CD4-positive precursor allows productive infection. J Virol (1997) 1.24
Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes. Retrovirology (2012) 1.14
Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. J Virol (2003) 1.11
Counteraction of the multifunctional restriction factor tetherin. Front Microbiol (2014) 1.09
Regions of human immunodeficiency virus type 1 nef required for function in vivo. J Virol (1998) 1.09
High viral burden and rapid CD4+ cell depletion in human immunodeficiency virus type 1-infected SCID-hu mice suggest direct viral killing of thymocytes in vivo. J Virol (1997) 1.09
Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol (1999) 1.09
Human immunodeficiency virus inhibits multilineage hematopoiesis in vivo. J Virol (1998) 1.04
The association of Nef with a cellular serine/threonine kinase and its enhancement of infectivity are viral isolate dependent. J Virol (1996) 1.03
Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy/Liv mice: evidence of indirect mechanisms. J Immunol (1999) 1.03
Human immunodeficiency virus type 1 Nef-induced CD4 cell surface downregulation is inhibited by ikarugamycin. J Virol (2001) 1.01
Separation of human immunodeficiency virus type 1 replication from nef-mediated pathogenesis in the human thymus. J Virol (2001) 1.00
HIV restriction by APOBEC3 in humanized mice. PLoS Pathog (2013) 1.00
HIV-1 replication and pathogenesis in the human thymus. Curr HIV Res (2003) 0.99
Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J Virol (2007) 0.98
Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J Virol (1997) 0.97
Induction of phosphorylation of human immunodeficiency virus type 1 Nef and enhancement of CD4 downregulation by phorbol myristate acetate. J Virol (1997) 0.95
Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol (1997) 0.94
Morphine and rapid disease progression in nonhuman primate model of AIDS: inverse correlation between disease progression and virus evolution. J Neuroimmune Pharmacol (2009) 0.91
Infectivity enhancement by human immunodeficiency virus type 1 Nef is independent of its association with a cellular serine/threonine kinase. J Virol (1997) 0.90
HIV-1 pathogenesis and therapeutic intervention in the SCID-hu Thy/Liv mouse: a model for primary HIV-1 infection in the human thymus. Rev Med Virol (1997) 0.89
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
Alteration of intracellular potassium and sodium concentrations correlates with induction of cytopathic effects by human immunodeficiency virus. J Virol (1996) 0.87
The expression of HIV-1 Vpu in monocytes causes increased secretion of TGF-β that activates profibrogenic genes in hepatic stellate cells. PLoS One (2014) 0.87
Vpu and BST2: Still Not There Yet? Front Microbiol (2012) 0.87
Reduced viral load and lack of CD4 depletion in SCID-hu mice infected with Rev-independent clones of human immunodeficiency virus type 1. J Virol (1997) 0.87
SIV Vpr evolution is inversely related to disease progression in a morphine-dependent rhesus macaque model of AIDS. Virology (2006) 0.84
Studies of retroviral infection in humanized mice. Virology (2015) 0.83
Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc Natl Acad Sci U S A (1998) 0.83
Involvement of a C-terminal motif in the interference of primate lentiviral Vpu proteins with CD1d-mediated antigen presentation. Sci Rep (2015) 0.81
HIV-1 Fitness and Replication Capacity: What Are They and Can They Help in Patient Management? Curr Infect Dis Rep (2003) 0.80
In vivo analysis of Nef's role in HIV-1 replication, systemic T cell activation and CD4(+) T cell loss. Retrovirology (2015) 0.79
Activation/proliferation and apoptosis of bystander goat lymphocytes induced by a macrophage-tropic chimeric caprine arthritis encephalitis virus expressing SIV Nef. Virology (2007) 0.78
Activation of the signal transducer and activator of transcription 1 signaling pathway in thymocytes from HIV-1-infected human thymus. AIDS (2003) 0.77
Identification and molecular characterization of SIV Vpr R50G mutation associated with long term survival in SIV-infected morphine dependent and control macaques. Virology (2013) 0.76
Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replication. Exp Biol Med (Maywood) (2017) 0.75
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science (1992) 9.30
The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (1988) 9.05
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature (1991) 6.79
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science (1995) 6.30
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature (1987) 5.45
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med (1994) 4.39
Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol (1990) 4.35
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol (1995) 4.19
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol (1994) 4.14
Progression to AIDS in the absence of a gene for vpr or vpx. J Virol (1995) 3.96
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
HIV induces thymus depletion in vivo. Nature (1993) 3.73
Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol (1995) 3.69
Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med (1990) 3.59
The SCID-hu mouse as a model for HIV-1 infection. Nature (1993) 3.43
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol (1993) 3.12
Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys. Cell (1995) 3.03
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell (1993) 2.90
The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages. Proc Natl Acad Sci U S A (1990) 2.84
Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med (1993) 2.81
Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses (1994) 2.72
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45
Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol (1994) 2.45
Expression of the type 1 human immunodeficiency virus Nef protein in T cells prevents antigen receptor-mediated induction of interleukin 2 mRNA. Proc Natl Acad Sci U S A (1991) 2.38
Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. J Virol (1994) 2.20
Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol (1995) 2.19
Cell-free transmission of Vif mutants of HIV-1. Virology (1992) 2.13
Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol (1995) 2.09
Role of vif during packing of the core of HIV-1. Virology (1994) 2.01
Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol (1993) 1.86
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol (1995) 1.69
Human immunodeficiency virus type 1 Nef protein inhibits NF-kappa B induction in human T cells. J Virol (1992) 1.59
vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol (1995) 1.51
Selective thymocyte depletion in neonatal HIV-1 thymic infection. AIDS (1993) 1.34
Thymic abnormalities in fetuses aborted from human immunodeficiency virus type 1 seropositive women. Pediatrics (1992) 1.28
In vivo pathogenic properties of two clonal human immunodeficiency virus type 1 isolates. J Virol (1995) 1.24
Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1. J Exp Med (1994) 1.22
Vpu-mediated proteolysis of gp160/CD4 chimeric envelope glycoproteins in the endoplasmic reticulum: requirement of both the anchor and cytoplasmic domains of CD4. Virology (1994) 0.99
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (2001) 6.84
HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity (2001) 3.43
The SCID-hu mouse as a model for HIV-1 infection. Nature (1993) 3.43
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis (1992) 3.27
Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol (1998) 3.09
High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science (1989) 3.00
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol (1993) 2.96
Generation of HIV latency during thymopoiesis. Nat Med (2001) 2.91
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol (1994) 2.45
Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol (1994) 2.36
Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). J Clin Invest (1992) 2.28
Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol (1990) 2.11
Generation of functional thymocytes in the human adult. Immunity (1999) 2.10
Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol (1999) 1.97
Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J Immunol (1998) 1.90
CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus. J Virol (1997) 1.88
In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol (1998) 1.73
Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc Natl Acad Sci U S A (2001) 1.68
Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood (1995) 1.62
Characterization and expression of novel singly spliced RNA species of human immunodeficiency virus type 1. J Virol (1990) 1.48
Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol (1998) 1.41
Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood (1994) 1.33
The mortality experience of workers exposed to tetrachlorodibenzodioxin in a trichlorophenol process accident. J Occup Med (1980) 1.27
Mechanism of human immunodeficiency virus type 1 localization in CD4-negative thymocytes: differentiation from a CD4-positive precursor allows productive infection. J Virol (1997) 1.24
In vivo pathogenic properties of two clonal human immunodeficiency virus type 1 isolates. J Virol (1995) 1.24
Detection of cell cycle subcompartments by flow cytometric estimation of DNA-RNA content in combination with dual-color immunofluorescence. Cytometry (2000) 1.22
Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat Med (1997) 1.21
Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells. Immunology (2001) 1.18
cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection. J Immunol (1999) 1.18
Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication. J Virol (2000) 1.12
Regions of human immunodeficiency virus type 1 nef required for function in vivo. J Virol (1998) 1.09
Differential tropism of HIV-1 isolates for distinct thymocyte subsets in vitro. AIDS (1996) 1.09
High viral burden and rapid CD4+ cell depletion in human immunodeficiency virus type 1-infected SCID-hu mice suggest direct viral killing of thymocytes in vivo. J Virol (1997) 1.09
Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol (1999) 1.09
Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha, and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain. J Exp Med (1995) 1.06
Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood (1993) 1.06
Human T-cell leukemia virus infection of human hematopoietic progenitor cells: maintenance of virus infection during differentiation in vitro and in vivo. J Virol (1996) 1.05
Human immunodeficiency virus inhibits multilineage hematopoiesis in vivo. J Virol (1998) 1.04
High-efficiency transduction of human lymphoid progenitor cells and expression in differentiated T cells. J Virol (1997) 1.03
The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS. Semin Immunol (1996) 1.02
In vitro studies of HIV-1 expression in thymocytes from infants and children. AIDS (1992) 0.97
Effect of cytokines on HIV-induced depletion of thymocytes in vivo. AIDS (2000) 0.96
Effects of cytokines on HIV-1 production by thymocytes. Thymus (1996) 0.96
Sequential determination of viral load and phenotype in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (1995) 0.95
Murine models for HIV disease. AIDS (1999) 0.95
Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 in fetal lymphoid organs: implications for pathogenesis in utero. AIDS Res Hum Retroviruses (1999) 0.94
Preparation and maintenance of SCID-hu mice for HIV research. Methods (1997) 0.92
Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy. J Virol (1999) 0.90
Isolation of mycobacterium-reactive CD1-restricted T cells from patients with human immunodeficiency virus infection. J Clin Invest (1998) 0.90
Reduced viral load and lack of CD4 depletion in SCID-hu mice infected with Rev-independent clones of human immunodeficiency virus type 1. J Virol (1997) 0.87
Loss of T cell receptor Vbeta repertoires in HIV type 1-infected SCID-hu mice. AIDS Res Hum Retroviruses (1997) 0.83
HIV-1 reverse transcription in cord blood lymphocytes: implications for infection of newborns. AIDS Res Hum Retroviruses (1994) 0.82
Recent advances in detection of human T-cell leukemia viruses type I and type II infection. Nat Immun Cell Growth Regul (1990) 0.80
Molecular pathogenesis of HIV-1. AIDS (1990) 0.80
HIV type 1 infection in lymphoid tissue: natural history and model systems. AIDS Res Hum Retroviruses (1998) 0.79
Functional reconstitution of thymopoiesis after human immunodeficiency virus infection. J Virol (2000) 0.79
Effects of megakaryocyte growth and development factor on survival and retroviral transduction of T lymphoid progenitor cells. Hum Gene Ther (1998) 0.79
Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice. J Pharmacol Exp Ther (1996) 0.78
Measurement of lymphocyte subset proliferation by three-color immunofluorescence and DNA flow cytometry. J Immunol Methods (2000) 0.77
Gene therapy for the treatment of AIDS: animal models and human clinical experience. Front Biosci (1999) 0.75
Rapid enzymatic analysis for human immunodeficiency virus type 1 DNA in clinical specimens. Clin Chem (1993) 0.75
Modeling human retroviral pathogenesis and antiretroviral gene therapy in the SCID mouse. Res Immunol (1994) 0.75
Federal policy. Stem-cell funds decision may have minimal impact on HIV/AIDS researchers. AIDS Policy Law (2001) 0.75